• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Growth inhibitory and anti-metastatic activity of epithelial cell adhesion molecule targeted three-way junctional Delta-5-Desaturase siRNA nanoparticle for breast cancer therapy
Publication date: Available online 12 September 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Harshit Shah, Lizhi Pang, Hongzhi Wang, Dan Shu, Steven Y. Qian, Venkatachalem Sathish
Source: Nanomedicine: Nanotechnology, Biology and Medicine - September 14, 2020 Category: Nanotechnology Source Type: research

Smart nanoparticles assembled by endogenous molecules for siRNA delivery and Cancer therapy via CD44 and EGFR dual-targeting
Publication date: Available online 21 October 2018Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Yaoyao Liang, Jiahui Peng, Ning Li, Cynthia Yu-Wai-Man, Qian Wang, Yuhong Xu, Hongxia Wang, Aristides D Tagalakis, Zixiu DuAbstractWe developed an anticancer siRNA delivery system (named HLPR) through modular assembly of endogenous molecules. The structure of HLPR was a tightly condensed siRNA-peptide inner core in turn surrounded by the disordered lipid layer and thin HA coating from which the EGFR-targeted amino acid sequences of IVNQPTYGYWHY partially protrude outside of cell surfaces. Both HA and IVNQP...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - October 21, 2018 Category: Nanotechnology Source Type: research

Mannose-conjugated layered double hydroxide nanocomposite for targeted siRNA delivery to enhance cancer therapy
Publication date: Available online 22 June 2017Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Li Li, Run Zhang, Wenyi Gu, Zhi Ping XuAbstractSheet-like layered double hydroxide nanoparticles (LDH NPs) have showed great potentials in biomedical applications such as nanocarriers for drug and gene delivery, biosensors and imaging agents. However, target delivery of drugs and genes using LDH NPs to the desired tumor sites is a major challenge in cancer therapy. The aim of this study is to develop a functional LDH-based nanocomposite for target delivery of siRNA to cancer cells. Mannose as a targeting moie...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 10, 2018 Category: Nanotechnology Source Type: research

Mannose-conjugated layered double hydroxide nanocomposite for targeted siRNA delivery to enhanced cancer therapy
Publication date: Available online 22 June 2017 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Li Li, Run Zhang, Wenyi Gu, Zhi Ping Xu Sheet-like layered double hydroxide nanoparticles (LDH NPs) have showed great potentials in biomedical applications such as nanocarriers for drug and gene delivery, biosensors and imaging agents. However, target delivery of drugs and genes using LDH NPs to the desired tumor sites is a major challenge in cancer therapy. The aim of this study is to develop a functional LDH-based nanocomposite for target delivery of siRNA to cancer cells. Mannose as a targeting moiety wa...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - June 23, 2017 Category: Nanotechnology Source Type: research

Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo
This study highlights the ability of incorporating a folate ligand into CD.siRNA nanoparticles to allow for targeted delivery of siRNA to prostate cancer cells via the PSMA. Graphical abstract
Source: Nanomedicine: Nanotechnology, Biology and Medicine - August 27, 2016 Category: Nanotechnology Source Type: research

Designing idiosyncratic hmPCL-siRNA Nanoformulated Capsules for Silencing and Cancer Therapy
Publication date: Available online 10 November 2015 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Vijay Bhooshon Kumar, Himadri Medhi, Zhang Yong, Pradip Paik In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~180 nm with shell thickness of 10-20 nm and mesopore size of ~5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In ...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 10, 2015 Category: Nanotechnology Source Type: research

Conformation-dependent binding and tumor-targeted delivery of siRNA by a designed TRBP2: Affibody fusion protein
Publication date: Available online 23 February 2015 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Ghulam Hassan Dar , Vijaya Gopal , Madhusudhana Rao Efficiency of systemically delivered siRNA in gene silencing is compromised due to lack of target-specific delivery and rapid clearance of siRNA by in vivo elimination pathways. We designed a fusion protein consisting of a dsRNA binding domain of Transactivation Response RNA Binding Protein (TRBP2) fused to ErbB2 binding affibody (AF) for target specific delivery of siRNA. Designated as TRAF, the fusion protein is stable and binds efficiently and spec...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - February 24, 2015 Category: Nanotechnology Source Type: research